ERBB2 AMPLIFICATION LEVEL AND PTPN2 GAIN AS POTENTIAL PROGNOSTIC FACTORS IN METASTATIC HER2-POSITIVE BREAST CANCER TREATED WITH TRASTUZUMAB

被引：0
|
作者：
Ellegard, Sander [1 ]
Veenstra, Cynthia [1 ]
Perez-Tenorio, Giseh [1 ]
Hallbeck, Anna-Lotta [1 ]
Elander, Nils [1 ]
Stal, Olle [1 ]
机构：
[1] Univ Hosp Linkoping, Oncol, Linkoping, Sweden
来源：
BREAST | 2017年 / 36卷
关键词：
D O I：
10.1016/S0960-9776(17)30690-2
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO71
引用
收藏
页码：S46 / S46
页数：1
相关论文
共 50 条
  • [1] ERBB2 and PTPN2 gene copy numbers as prognostic factors in HER2-positive metastatic breast cancer treated with trastuzumab
    Ellegard, Sander
    Veenstra, Cynthia
    Perez-Tenorio, Gizeh
    Fagerstrom, Victor
    Garsjo, Jon
    Gert, Krista
    Sundquist, Marie
    Malmstrom, Annika
    Wingren, Sten
    Elander, Nils O.
    Hallbeck, Anna-Lotta
    Stal, Olle
    ONCOLOGY LETTERS, 2019, 17 (03) : 3371 - 3381
  • [2] Palindromic amplification of the ERBB2 oncogene in primary HER2-positive breast tumors
    Michael Marotta
    Taku Onodera
    Jeffrey Johnson
    G. Thomas Budd
    Takaaki Watanabe
    Xiaojiang Cui
    Armando E. Giuliano
    Atsushi Niida
    Hisashi Tanaka
    Scientific Reports, 7
  • [3] Palindromic amplification of the ERBB2 oncogene in primary HER2-positive breast tumors
    Marotta, Michael
    Onodera, Taku
    Johnson, Jeffrey
    Budd, G. Thomas
    Watanabe, Takaaki
    Cui, Xiaojiang
    Giuliano, Armando E.
    Niida, Atsushi
    Tanaka, Hisashi
    SCIENTIFIC REPORTS, 2017, 7
  • [4] Trastuzumab emtansine in HER2-positive metastatic breast cancer
    Montemurro, Filippo
    LANCET ONCOLOGY, 2017, 18 (06): : 696 - 697
  • [5] Trastuzumab therapy in HER2-positive, metastatic breast cancer
    Smith, A. D.
    Guilbert, K.
    Lister, D.
    Streilein, S.
    Bourrier, V. C.
    Lozar, B.
    Navaratnam, S.
    Harding, G. A.
    Pitz, M. W.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [6] Trastuzumab Deruxtecan in HER2-positive metastatic Breast Cancer
    Lorenz, Judith
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2024, 84 (08) : 670 - 670
  • [7] Factors influencing survival among patients with HER2-positive metastatic breast cancer treated with trastuzumab
    P. S. Blanchette
    D. N. Desautels
    G. R. Pond
    J. M. S. Bartlett
    S. Nofech-Mozes
    M. J. Yaffe
    K. I. Pritchard
    Breast Cancer Research and Treatment, 2018, 170 : 169 - 177
  • [8] Factors influencing survival among patients with HER2-positive metastatic breast cancer treated with Trastuzumab
    Blanchette, P. S.
    Desautels, D. N.
    Pond, G.
    Bartlett, J. M. S.
    Nofech-Mozes, S.
    Yaffe, M.
    Pritchard, K. I.
    CANCER RESEARCH, 2017, 77
  • [9] Factors influencing survival among patients with HER2-positive metastatic breast cancer treated with trastuzumab
    Blanchette, P. S.
    Desautels, D. N.
    Pond, G. R.
    Bartlett, J. M. S.
    Nofech-Mozes, S.
    Yaffe, M. J.
    Pritchard, K. I.
    BREAST CANCER RESEARCH AND TREATMENT, 2018, 170 (01) : 169 - 177
  • [10] Topoisomerase II alpha gene amplification is a favorable prognostic factor in patients with HER2-positive metastatic breast cancer treated with trastuzumab
    Fountzilas, George
    Christodoulou, Christos
    Bobos, Mattheos
    Kotoula, Vassiliki
    Eleftheraki, Anastasia G.
    Xanthakis, Ioannis
    Batistatou, Anna
    Pentheroudakis, George
    Xiros, Nikolaos
    Papaspirou, Irene
    Koumarianou, Anna
    Papakostas, Pavlos
    Bafaloukos, Dimitrios
    Skarlos, Dimosthenis V.
    Kalogeras, Konstantine T.
    JOURNAL OF TRANSLATIONAL MEDICINE, 2012, 10
12345